Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913296 | 0.82 | DAO (0.59) | KDM4EPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL12241447 | 0.82 | CHEK1 (0.59) | KDM4EPARP1HSD17B10CHEK1PIM1 | |
| SCHEMBL20792931 | 0.74 | PARP1 (0.56) | KDM4EPARP1HSD17B10CHEK1LMNA | |
| SCHEMBL12241457 | 0.74 | PARP1 (0.49) | KDM4EPARP1HSD17B10CHEK1PIM1 | |
| SCHEMBL24000182 | 0.74 | GRIN2D (0.48) | KDM4EHSD17B10CHEK1PIM1RPS6KA3 | |
| SCHEMBL21729422 | 0.73 | KDM4E (0.52) | KDM4EHSD17B10LMNAALDH1A1DAO | |
| SCHEMBL25839255 | 0.73 | CHEK1 (0.44) | PARP1CHEK1PIM1RPS6KA3LMNA | |
| SCHEMBL24000186 | 0.73 | CHEK1 (0.44) | PARP1CHEK1PIM1RPS6KA3LMNA | |
| SCHEMBL13527428 | 0.73 | KDM4E (0.48) | KDM4EHSD17B10CHEK1PIM1RPS6KA3 | |
| SCHEMBL183181 | 0.71 | PARP15 (0.50) | KDM4EPARP1HSD17B10ALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4861778-A | 2,3-dihydrophthalazine-1,4-diones | RESEARCH CORPORATION (US) | 1989-08-29 | — | — | US | claimed |
| US-4207112-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1980-06-10 | — | — | US | claimed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | ORIGIANT PHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4410787-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | Origiant Pharmaceutical Co., Ltd (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070020715-A1 | Novel fluorogenic substrates for beta-lactamase gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-01-25 | — | — | US | disclosed |
| US-7157575-B2 | Substrates for β-lactamase and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-4861778-A | 2,3-dihydrophthalazine-1,4-diones | RESEARCH CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| US-4207112-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4076534-A | Heat developable light-sensitive material | FUJI PHOTO FILM CO., LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | KDM4E 3867/4885PARP1 995/4885HSD17B10 1551/4885 |
| US-20070020715-A1 | Novel fluorogenic substrates for beta-lactamase gene expression | CMBL, HRH3, TDO2 | KDM4E 1516/4885PARP1 4615/4885HSD17B10 91/4885 |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | KDM4E 2467/4885PARP1 786/4885HSD17B10 1833/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | KDM4E 2467/4885PARP1 786/4885HSD17B10 1833/4885 |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | KDM4E 3062/4885PARP1 400/4885HSD17B10 1543/4885 |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | NLRP3, NLRP1, NOD1 | KDM4E 3999/4885PARP1 750/4885HSD17B10 252/4885 |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | CMBL, DBH, NCEH1 | KDM4E 886/4885PARP1 4409/4885HSD17B10 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.